Nilotinib
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Nilotinib: From Undocumented Original Indication to Dermatofibrosarcoma Protuberans
One-Sentence Summary
The evidence pack does not include a documented original indication or approved license for nilotinib in this market — mechanism-of-action data confirms it is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR-ABL and PDGFR. The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), but this direction is currently supported by 0 clinical trials and only 1 publication (a general PDGFR-inhibitor review, not nilotinib/DFSP-specific).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (no license/approved indication on file) |
| Predicted New Indication | Dermatofibrosarcoma Protuberans (DFSP) |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| Finland Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed original-indication and formal MOA fields are marked as data gaps in this evidence pack. However, the repurposing rationale attached to the DFSP prediction indicates that nilotinib is a second-generation tyrosine kinase inhibitor that, in addition to BCR-ABL, also inhibits PDGFR — the same target implicated in DFSP pathogenesis.
DFSP is characterized in most cases by a COL1A1-PDGFB fusion gene, which drives constitutive PDGFRB activation and tumour proliferation. Because nilotinib inhibits PDGFR, there is a plausible mechanistic rationale for activity in DFSP. This is reinforced by class-level precedent: imatinib, a related TKI with PDGFR-inhibitory activity, already has established clinical evidence (including approved indications in some regions) for DFSP.
That said, this is currently a class-level analogy rather than nilotinib-specific evidence — the single supporting publication is a general review of PDGFR-inhibitor pharmacology, not a nilotinib/DFSP clinical or case study. Nilotinib's own applicability to DFSP has not yet been independently demonstrated.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological research | Reviews the role of small-molecule PDGFR inhibitors (a class including nilotinib) in treating neoplastic disorders driven by PDGF/PDGFR signaling; not specific to nilotinib or DFSP clinical outcomes |
Finland Market Information
No marketing authorizations are on file for nilotinib in this market (market status: Not Marketed, 0 licenses).
Cytotoxicity
Nilotinib is an antineoplastic agent (tyrosine kinase inhibitor targeting BCR-ABL/PDGFR).
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is currently limited to a mechanistic class-level analogy (L4, decision stage S1 "Research Question") with no nilotinib-specific clinical trials or literature for DFSP, and a Blocking data gap on package-insert safety information (DG001) prevents even an initial safety screen (S1).
To proceed, the following is needed:
- TFDA/local package insert warnings and contraindications (DG001, Blocking)
- Confirmed mechanism of action documentation from DrugBank (DG002)
- Nilotinib-specific clinical or case-level evidence in DFSP (current literature is class-level only)
- Drug-drug interaction data (currently not found)
- Original approved indication and licensing history for baseline comparison
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.